Premium
Emerging roles of RAC1 in treating lung cancer patients
Author(s) -
Zou T.,
Mao X.,
Yin J.,
Li X.,
Chen J.,
Zhu T.,
Li Q.,
Zhou H.,
Liu Z.
Publication year - 2017
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.12908
Subject(s) - rac1 , lung cancer , cancer , cancer research , angiogenesis , cancer cell , medicine , biology , microbiology and biotechnology , signal transduction
The Ras‐related C3 botulinum toxin substrate 1 ( RAC1 ), a member of the Rho family of small guanosine triphosphatases, is critical for many cellular activities, such as phagocytosis, adhesion, migration, motility, cell proliferation, and axonal growth. In addition, RAC1 plays an important role in cancer angiogenesis, invasion, and migration, and it has been reported to be related to most cancers, such as breast cancer, gastric cancer, testicular germ cell cancer, and lung cancer. Recently, the therapeutic target of RAC1 in cancer has been investigated. In addition, some investigations have shown that inhibition of RAC1 can reverse drug‐resistance in non‐small cell lung cancer. In this review, we summarize the recent advances in understanding the role of RAC1 in lung cancer and the underlying mechanisms and discuss its value in clinical therapy.